Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma.

Chen KS, Bridges CR, Lynton Z, Lim JWC, Stringer BW, Rajagopal R, Wong KT, Ganesan D, Ariffin H, Day BW, Richards LJ, Bunt J.

J Neurooncol. 2019 Nov 23. doi: 10.1007/s11060-019-03352-3. [Epub ahead of print]

PMID:
31760595
2.

Circulating biomarkers in patients with glioblastoma.

Müller Bark J, Kulasinghe A, Chua B, Day BW, Punyadeera C.

Br J Cancer. 2019 Oct 31. doi: 10.1038/s41416-019-0603-6. [Epub ahead of print] Review.

PMID:
31666668
3.

Simultaneous Targeting of DNA Replication and Homologous Recombination in Glioblastoma with a Polyether Ionophore.

Lim YC, Ensbey KS, Offenhäuser C, D'Souza RCJ, Cullen JK, Stringer BW, Quek H, Bruce ZC, Kijas A, Cianfanelli V, Mahboubi B, Smith F, Jeffree RL, Wiesmüeller L, Wiegmans AP, Bain A, Lombard FJ, Roberts TL, Khanna KK, Lavin MF, Baek K, Hamerlik P, Johns TG, Coster MJ, Boyd AW, Day BW.

Neuro Oncol. 2019 Aug 30. pii: noz159. doi: 10.1093/neuonc/noz159. [Epub ahead of print]

PMID:
31504812
4.

The dystroglycan receptor maintains glioma stem cells in the vascular niche.

Day BW, Lathia JD, Bruce ZC, D'Souza RCJ, Baumgartner U, Ensbey KS, Lim YC, Stringer BW, Akgül S, Offenhäuser C, Li Y, Jamieson PR, Smith FM, Jurd CLR, Robertson T, Inglis PL, Lwin Z, Jeffree RL, Johns TG, Bhat KPL, Rich JN, Campbell KP, Boyd AW.

Acta Neuropathol. 2019 Dec;138(6):1033-1052. doi: 10.1007/s00401-019-02069-x. Epub 2019 Aug 28.

5.
6.

A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma.

Stringer BW, Day BW, D'Souza RCJ, Jamieson PR, Ensbey KS, Bruce ZC, Lim YC, Goasdoué K, Offenhäuser C, Akgül S, Allan S, Robertson T, Lucas P, Tollesson G, Campbell S, Winter C, Do H, Dobrovic A, Inglis PL, Jeffree RL, Johns TG, Boyd AW.

Sci Rep. 2019 Mar 20;9(1):4902. doi: 10.1038/s41598-019-41277-z.

7.

Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma.

Akgül S, Patch AM, D'Souza RCJ, Mukhopadhyay P, Nones K, Kempe S, Kazakoff SH, Jeffree RL, Stringer BW, Pearson JV, Waddell N, Day BW.

Cancers (Basel). 2019 Feb 6;11(2). pii: E190. doi: 10.3390/cancers11020190.

8.

EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma.

Offenhäuser C, Al-Ejeh F, Puttick S, Ensbey KS, Bruce ZC, Jamieson PR, Smith FM, Stringer BW, Carrington B, Fuchs AV, Bell CA, Jeffree R, Rose S, Thurecht KJ, Boyd AW, Day BW.

Cancers (Basel). 2018 Dec 17;10(12). pii: E519. doi: 10.3390/cancers10120519.

9.

Granule neuron precursor cell proliferation is regulated by NFIX and intersectin 1 during postnatal cerebellar development.

Fraser J, Essebier A, Brown AS, Davila RA, Sengar AS, Tu Y, Ensbey KS, Day BW, Scott MP, Gronostajski RM, Wainwright BJ, Boden M, Harvey TJ, Piper M.

Brain Struct Funct. 2019 Mar;224(2):811-827. doi: 10.1007/s00429-018-1801-3. Epub 2018 Dec 3.

PMID:
30511336
10.

Extracellular Vesicles Released by Glioblastoma Cells Stimulate Normal Astrocytes to Acquire a Tumor-Supportive Phenotype Via p53 and MYC Signaling Pathways.

Hallal S, Mallawaaratchy DM, Wei H, Ebrahimkhani S, Stringer BW, Day BW, Boyd AW, Guillemin GJ, Buckland ME, Kaufman KL.

Mol Neurobiol. 2019 Jun;56(6):4566-4581. doi: 10.1007/s12035-018-1385-1. Epub 2018 Oct 23.

11.

Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma.

Neubauer HA, Tea MN, Zebol JR, Gliddon BL, Stefanidis C, Moretti PAB, Pitman MR, Costabile M, Kular J, Stringer BW, Day BW, Samuel MS, Bonder CS, Powell JA, Pitson SM.

Oncogene. 2019 Feb;38(8):1151-1165. doi: 10.1038/s41388-018-0504-9. Epub 2018 Sep 24.

12.

Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors.

Hoque M, Abbassi RH, Froio D, Man J, Johns TG, Stringer BW, Day BW, Pajic M, Kassiou M, Munoz L.

Pharmacol Res. 2018 Aug;134:166-178. doi: 10.1016/j.phrs.2018.06.023. Epub 2018 Jun 23.

PMID:
29944980
13.

Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma.

Greenall SA, Lim YC, Mitchell CB, Ensbey KS, Stringer BW, Wilding AL, O'Neill GM, McDonald KL, Gough DJ, Day BW, Johns TG.

Oncogenesis. 2017 May 15;6(5):e336. doi: 10.1038/oncsis.2017.33.

14.

Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma.

Gilabert-Oriol R, Furness SGB, Stringer BW, Weng A, Fuchs H, Day BW, Kourakis A, Boyd AW, Hare DL, Thakur M, Johns TG, Wookey PJ.

Cancer Immunol Immunother. 2017 Sep;66(9):1217-1228. doi: 10.1007/s00262-017-2013-z. Epub 2017 May 13.

PMID:
28501939
15.

Development and Biological Evaluation of a Photoactivatable Small Molecule Microtubule-Targeting Agent.

Döbber A, Phoa AF, Abbassi RH, Stringer BW, Day BW, Johns TG, Abadleh M, Peifer C, Munoz L.

ACS Med Chem Lett. 2017 Mar 15;8(4):395-400. doi: 10.1021/acsmedchemlett.6b00483. eCollection 2017 Apr 13.

16.

Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma.

Zhou Q, Phoa AF, Abbassi RH, Hoque M, Reekie TA, Font JS, Ryan RM, Stringer BW, Day BW, Johns TG, Munoz L, Kassiou M.

J Med Chem. 2017 Mar 9;60(5):2052-2070. doi: 10.1021/acs.jmedchem.6b01840. Epub 2017 Feb 28.

PMID:
28206758
17.

Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.

Tivnan A, Heilinger T, Ramsey JM, O'Connor G, Pokorny JL, Sarkaria JN, Stringer BW, Day BW, Boyd AW, Kim EL, Lode HN, Cryan SA, Prehn JH.

Oncotarget. 2017 Mar 7;8(10):16605-16620. doi: 10.18632/oncotarget.15073.

18.

A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity.

Kaltenmeier CT, Vollmer LL, Vernetti LA, Caprio L, Davis K, Korotchenko VN, Day BW, Tsang M, Hulkower KI, Lotze MT, Vogt A.

J Pharmacol Exp Ther. 2017 Apr;361(1):39-50. doi: 10.1124/jpet.116.239756. Epub 2017 Feb 2.

19.

Total Synthesis and Biological Evaluation of Tubulysin Analogues.

Colombo R, Wang Z, Han J, Balachandran R, Daghestani HN, Camarco DP, Vogt A, Day BW, Mendel D, Wipf P.

J Org Chem. 2016 Nov 4;81(21):10302-10320. Epub 2016 Aug 5.

PMID:
27447195
20.

Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma.

Stringer BW, Bunt J, Day BW, Barry G, Jamieson PR, Ensbey KS, Bruce ZC, Goasdoué K, Vidal H, Charmsaz S, Smith FM, Cooper LT, Piper M, Boyd AW, Richards LJ.

Oncotarget. 2016 May 17;7(20):29306-20. doi: 10.18632/oncotarget.8720.

21.

Differential response of patient-derived primary glioblastoma cells to environmental stiffness.

Grundy TJ, De Leon E, Griffin KR, Stringer BW, Day BW, Fabry B, Cooper-White J, O'Neill GM.

Sci Rep. 2016 Mar 21;6:23353. doi: 10.1038/srep23353.

22.

Synthesis and evaluation of orally active small molecule HIV-1 Nef antagonists.

Emert-Sedlak LA, Loughran HM, Shi H, Kulp JL 3rd, Shu ST, Zhao J, Day BW, Wrobel JE, Reitz AB, Smithgall TE.

Bioorg Med Chem Lett. 2016 Mar 1;26(5):1480-1484. doi: 10.1016/j.bmcl.2016.01.043. Epub 2016 Jan 21.

23.

Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.

Zakaria Z, Tivnan A, Flanagan L, Murray DW, Salvucci M, Stringer BW, Day BW, Boyd AW, Kögel D, Rehm M, O'Brien DF, Byrne AT, Prehn JH.

Br J Cancer. 2016 Jan 19;114(2):188-98. doi: 10.1038/bjc.2015.420. Epub 2015 Dec 10.

24.

The point mutation UCH-L1 C152A protects primary neurons against cyclopentenone prostaglandin-induced cytotoxicity: implications for post-ischemic neuronal injury.

Liu H, Li W, Rose ME, Hickey RW, Chen J, Uechi GT, Balasubramani M, Day BW, Patel KV, Graham SH.

Cell Death Dis. 2015 Nov 5;6:e1966. doi: 10.1038/cddis.2015.323.

25.

Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling.

Phoa AF, Browne S, Gurgis FM, Åkerfeldt MC, Döbber A, Renn C, Peifer C, Stringer BW, Day BW, Wong C, Chircop M, Johns TG, Kassiou M, Munoz L.

Biochem Pharmacol. 2015 Dec 15;98(4):587-601. doi: 10.1016/j.bcp.2015.10.014. Epub 2015 Oct 28.

PMID:
26519552
26.

EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study.

Puttick S, Stringer BW, Day BW, Bruce ZC, Ensbey KS, Mardon K, Cowin GJ, Thurecht KJ, Whittaker AK, Fay M, Boyd AW, Rose S.

Mol Imaging. 2015;14:385-99.

PMID:
26218510
27.

N-(1'-naphthyl)-3,4,5-trimethoxybenzohydrazide as microtubule destabilizer: Synthesis, cytotoxicity, inhibition of cell migration and in vivo activity against acute lymphoblastic leukemia.

Salum LB, Mascarello A, Canevarolo RR, Altei WF, Laranjeira AB, Neuenfeldt PD, Stumpf TR, Chiaradia-Delatorre LD, Vollmer LL, Daghestani HN, de Souza Melo CP, Silveira AB, Leal PC, Frederico MJ, do Nascimento LF, Santos AR, Andricopulo AD, Day BW, Yunes RA, Vogt A, Yunes JA, Nunes RJ.

Eur J Med Chem. 2015;96:504-18. doi: 10.1016/j.ejmech.2015.02.041. Epub 2015 Feb 23.

PMID:
25951294
28.

Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines.

Rahman M, Reyner K, Deleyrolle L, Millette S, Azari H, Day BW, Stringer BW, Boyd AW, Johns TG, Blot V, Duggal R, Reynolds BA.

Anat Cell Biol. 2015 Mar;48(1):25-35. doi: 10.5115/acb.2015.48.1.25. Epub 2015 Mar 20.

29.

Eph family co-expression patterns define unique clusters predictive of cancer phenotype.

Al-Ejeh F, Offenhäuser C, Lim YC, Stringer BW, Day BW, Boyd AW.

Growth Factors. 2014 Dec;32(6):254-64. doi: 10.3109/08977194.2014.984807. Epub 2014 Nov 20. Review.

PMID:
25410964
30.

Eph receptors as therapeutic targets in glioblastoma.

Day BW, Stringer BW, Boyd AW.

Br J Cancer. 2014 Sep 23;111(7):1255-61. doi: 10.1038/bjc.2014.73. Epub 2014 Aug 21. Review.

31.

Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells.

Lim YC, Roberts TL, Day BW, Stringer BW, Kozlov S, Fazry S, Bruce ZC, Ensbey KS, Walker DG, Boyd AW, Lavin MF.

Mol Oncol. 2014 Dec;8(8):1603-15. doi: 10.1016/j.molonc.2014.06.012. Epub 2014 Jun 27.

32.

Structure elucidation of phase I metabolites of the microtubule perturbagens: ceratamines A and B.

Smith SE, Dello Buono MC, Carper DJ, Coleman RS, Day BW.

J Nat Prod. 2014 Jul 25;77(7):1572-8. doi: 10.1021/np4010882. Epub 2014 Jun 25.

PMID:
24964362
33.

In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase.

Korotchenko VN, Saydmohammed M, Vollmer LL, Bakan A, Sheetz K, Debiec KT, Greene KA, Agliori CS, Bahar I, Day BW, Vogt A, Tsang M.

Chembiochem. 2014 Jul 7;15(10):1436-45. doi: 10.1002/cbic.201402000. Epub 2014 Jun 6.

34.

The anti-promyelocytic leukemia mode of action of two endophytic secondary metabolites unveiled by a proteomic approach.

Gallo MB, Falso MJ, Balem F, Menezes D, Rocha N, Balachandran R, Sturgeon TS, Pupo MT, Day BW.

Planta Med. 2014 Apr;80(6):473-81. doi: 10.1055/s-0034-1368301. Epub 2014 Apr 7.

PMID:
24710897
35.

Synthesis and structure-activity analysis of diphenylpyrazolodiazene inhibitors of the HIV-1 Nef virulence factor.

Iyer PC, Zhao J, Emert-Sedlak LA, Moore KK, Smithgall TE, Day BW.

Bioorg Med Chem Lett. 2014 Apr 1;24(7):1702-6. doi: 10.1016/j.bmcl.2014.02.045. Epub 2014 Feb 26.

36.

NFIB-mediated repression of the epigenetic factor Ezh2 regulates cortical development.

Piper M, Barry G, Harvey TJ, McLeay R, Smith AG, Harris L, Mason S, Stringer BW, Day BW, Wray NR, Gronostajski RM, Bailey TL, Boyd AW, Richards LJ.

J Neurosci. 2014 Feb 19;34(8):2921-30. doi: 10.1523/JNEUROSCI.2319-13.2014.

37.

Determination of warfarin alcohols by ultra-high performance liquid chromatography-tandem mass spectrometry: application to in vitro enzyme kinetic studies.

Alshogran OY, Ocque AJ, Zhao J, Day BW, Leblond FA, Pichette V, Nolin TD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jan 1;944:63-8. doi: 10.1016/j.jchromb.2013.11.014. Epub 2013 Nov 14.

PMID:
24291722
38.

A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis.

Abuhusain HJ, Matin A, Qiao Q, Shen H, Kain N, Day BW, Stringer BW, Daniels B, Laaksonen MA, Teo C, McDonald KL, Don AS.

J Biol Chem. 2013 Dec 27;288(52):37355-64. doi: 10.1074/jbc.M113.494740. Epub 2013 Nov 21.

39.

Discovery of a diaminoquinoxaline benzenesulfonamide antagonist of HIV-1 Nef function using a yeast-based phenotypic screen.

Trible RP, Narute P, Emert-Sedlak LA, Alvarado JJ, Atkins K, Thomas L, Kodama T, Yanamala N, Korotchenko V, Day BW, Thomas G, Smithgall TE.

Retrovirology. 2013 Nov 14;10:135. doi: 10.1186/1742-4690-10-135.

40.

Glioma surgical aspirate: a viable source of tumor tissue for experimental research.

Day BW, Stringer BW, Wilson J, Jeffree RL, Jamieson PR, Ensbey KS, Bruce ZC, Inglis P, Allan S, Winter C, Tollesson G, Campbell S, Lucas P, Findlay W, Kadrian D, Johnson D, Robertson T, Johns TG, Bartlett PF, Osborne GW, Boyd AW.

Cancers (Basel). 2013 Apr 3;5(2):357-71. doi: 10.3390/cancers5020357.

41.

The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma.

Tivnan A, Zhao J, Johns TG, Day BW, Stringer BW, Boyd AW, Tiwari S, Giles KM, Teo C, McDonald KL.

Tumour Biol. 2014 Feb;35(2):1459-65. doi: 10.1007/s13277-013-1200-6. Epub 2013 Sep 26.

PMID:
24068568
42.

Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake.

Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, Weil RJ, Nakano I, Sarkaria JN, Stringer BW, Day BW, Li M, Lathia JD, Rich JN, Hjelmeland AB.

Nat Neurosci. 2013 Oct;16(10):1373-82. doi: 10.1038/nn.3510. Epub 2013 Sep 1.

43.

Histone deacetylase inhibitor enhances recovery after AKI.

Cianciolo Cosentino C, Skrypnyk NI, Brilli LL, Chiba T, Novitskaya T, Woods C, West J, Korotchenko VN, McDermott L, Day BW, Davidson AJ, Harris RC, de Caestecker MP, Hukriede NA.

J Am Soc Nephrol. 2013 May;24(6):943-53. doi: 10.1681/ASN.2012111055. Epub 2013 Apr 25.

44.

Elevated 4-aminobiphenyl and 2,6-dimethylaniline hemoglobin adducts and increased risk of bladder cancer among lifelong nonsmokers--The Shanghai Bladder Cancer Study.

Tao L, Day BW, Hu B, Xiang YB, Wang R, Stern MC, Gago-Dominguez M, Cortessis VK, Conti DV, Van Den Berg D, Pike MC, Gao YT, Yu MC, Yuan JM.

Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):937-45. doi: 10.1158/1055-9965.EPI-12-1447. Epub 2013 Mar 28.

45.

Cytotoxic 3,4,5-trimethoxychalcones as mitotic arresters and cell migration inhibitors.

Salum LB, Altei WF, Chiaradia LD, Cordeiro MN, Canevarolo RR, Melo CP, Winter E, Mattei B, Daghestani HN, Santos-Silva MC, Creczynski-Pasa TB, Yunes RA, Yunes JA, Andricopulo AD, Day BW, Nunes RJ, Vogt A.

Eur J Med Chem. 2013 May;63:501-10. doi: 10.1016/j.ejmech.2013.02.037. Epub 2013 Mar 6.

46.

EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.

Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhäuser C, Charmsaz S, Cooper LT, Ellacott JK, Harding A, Leveque L, Inglis P, Allan S, Walker DG, Lackmann M, Osborne G, Khanna KK, Reynolds BA, Lickliter JD, Boyd AW.

Cancer Cell. 2013 Feb 11;23(2):238-48. doi: 10.1016/j.ccr.2013.01.007.

47.

Gallium(III) complexes with 2-acetylpyridine-derived thiosemicarbazones: antimicrobial and cytotoxic effects and investigation on the interactions with tubulin.

Lessa JA, Soares MA, dos Santos RG, Mendes IC, Salum LB, Daghestani HN, Andricopulo AD, Day BW, Vogt A, Beraldo H.

Biometals. 2013 Feb;26(1):151-65. doi: 10.1007/s10534-012-9603-1. Epub 2013 Jan 24.

PMID:
23344786
48.

Development and validation of a high-content screening assay to identify inhibitors of cytoplasmic dynein-mediated transport of glucocorticoid receptor to the nucleus.

Johnston PA, Shinde SN, Hua Y, Shun TY, Lazo JS, Day BW.

Assay Drug Dev Technol. 2012 Oct;10(5):432-56. doi: 10.1089/adt.2012.456. Epub 2012 Jul 25.

49.

A role for homologous recombination and abnormal cell-cycle progression in radioresistance of glioma-initiating cells.

Lim YC, Roberts TL, Day BW, Harding A, Kozlov S, Kijas AW, Ensbey KS, Walker DG, Lavin MF.

Mol Cancer Ther. 2012 Sep;11(9):1863-72. doi: 10.1158/1535-7163.MCT-11-1044. Epub 2012 Jul 6.

50.

Synthesis and biological properties of C-2 triazolylinosine derivatives.

Lakshman MK, Kumar A, Balachandran R, Day BW, Andrei G, Snoeck R, Balzarini J.

J Org Chem. 2012 Jul 20;77(14):5870-83. doi: 10.1021/jo300628y. Epub 2012 Jul 3.

Supplemental Content

Support Center